Stage IV ALK Lung Adenocarcinoma: Niko's Patient Story
This lung cancer diagnosis at a glance
- Stage at diagnosis
- Stage IV
- Subtype
- Adenocarcinoma
- Biomarkers
- ALK mutation/rearrangement
- Sex
- Female
- Spread to
- Lymph nodes; Brain
- Treatment
- targeted therapy
- Outcome
- Responding Well
Treatment course, step by step
- Pleural effusion drainage and testing led to ALK-positive lung adenocarcinoma diagnosis
- PET-CT and brain MRI showed lymph-node disease and scattered brain lesions
- Started a second-generation ALK targeted drug and stayed on it for about 1.5 years
- After resistance developed, switched to a third-generation ALK targeted drug for about 8-9 months
- Side effects included weight gain, swelling, numbness, high cholesterol, itching, and eczema-like rash
- Latest MRI/PET-CT after 6 months on third-generation therapy showed no brain lesion and stable/dormant active disease.
What happened, in summary
Niko was diagnosed with lung adenocarcinoma about 2 years before the May 2024 interview. The first sign was frequent coughing during the COVID period. A doctor listened to her chest, suspected pleural effusion, ordered a chest X-ray, and sent her to the hospital. The pleural fluid was drained and tested, and genetic testing showed ALK-positive lung cancer. Additional PET-CT and brain MRI found disease in lymph nodes and scattered brain lesions, confirming Stage IV disease. Niko started a second-generation ALK targeted drug at diagnosis. She stayed on it for about 1.5 years before resistance developed, then moved to a third-generation ALK targeted drug for about 8-9 months. Neither ALK drug is named. Side effects were more noticeable on third-generation treatment: rapid weight gain, edema, numbness in the hands and feet, high cholesterol that required medication, itching, eczema-like rash, and prurigo-type skin problems. Even so, she described targeted therapy as easier than conventional chemotherapy because it was oral treatment and her cancer was well controlled. After 6 months on third-generation treatment, MRI and PET-CT showed no brain lesion, and previously active disease had become dormant and stable. As of May 2024, Niko remained on long-term targeted therapy with responding Stage IV ALK-positive lung cancer.
Where this story comes from
This is a lay summary of an account first published by YouTube (ZH search). Read the original in full
These are lay summaries of published cancer stories, for information only. No two cancers behave the same way, and nothing here predicts your own diagnosis or replaces advice from your oncology team.